



## Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine

This information is current as of April 16, 2012

Takahiro Okazaki, C. David Pendleton, Pablo Sarobe, Elaine K. Thomas, Sujatha Iyengar, Clayton Harro, David Schwartz and Jay A. Berzofsky

*J Immunol* 2006;176:3753-3759

- 
- References** This article **cites 34 articles**, 17 of which can be accessed free at: <http://www.jimmunol.org/content/176/6/3753.full.html#ref-list-1>
- Subscriptions** Information about subscribing to *The Journal of Immunology* is online at <http://www.jimmunol.org/subscriptions>
- Permissions** Submit copyright permission requests at <http://www.aai.org/ji/copyright.html>
- Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at <http://www.jimmunol.org/etoc/subscriptions.shtml/>



# Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine<sup>1</sup>

Takahiro Okazaki,<sup>2\*</sup> C. David Pendleton,\* Pablo Sarobe,<sup>3\*</sup> Elaine K. Thomas,<sup>4†</sup> Sujatha Iyengar,<sup>‡</sup> Clayton Harro,<sup>‡</sup> David Schwartz,<sup>‡</sup> and Jay A. Berzofsky<sup>5\*</sup>

Virus-specific CD4<sup>+</sup> T cell help and CD8<sup>+</sup> cytotoxic T cell responses are critical for maintenance of effective immunity in chronic viral infections. The importance of CD4<sup>+</sup> T cells has been documented in HIV infection. To investigate whether a stronger CD4<sup>+</sup> T cell response can be induced by modifications to enhance the T1 epitope, the first CD4<sup>+</sup> T cell epitope discovered in HIV-1-gp120, we developed a T1-specific CD4<sup>+</sup> T cell line from a healthy volunteer immunized with a canarypox vector expressing gp120 and boosted with recombinant gp120. This T1-specific CD4<sup>+</sup> T cell line was restricted to DR13, which is common in U.S. Caucasians and African-Americans and very frequent in Africans. Peptides with certain amino acid substitutions in key positions induced enhanced specific CD4<sup>+</sup> T cell proliferative responses at lower peptide concentration than the original epitope. This relatively conserved CD4 epitope improved by the epitope enhancement strategy could be a component of a more effective second generation vaccine construct for HIV infection. *The Journal of Immunology*, 2006, 176: 3753–3759.

The CD4<sup>+</sup> T cell help plays a critical role in maintaining CTL function in viral infection (1–5). In HIV-infected patients, a quantitative decline in the number of CD4<sup>+</sup> lymphocytes and a qualitative impairment of CD4<sup>+</sup> T cell function lead to AIDS. However, the HIV-specific CD4<sup>+</sup> T cell response can be recovered after initiation of highly active antiretroviral therapy. This recovery is inversely correlated with HIV viral load (5, 6). In mice, CD4<sup>+</sup> T cells are required for expansion and memory of CD8<sup>+</sup> CTLs (7–9), suggesting that stronger CD4<sup>+</sup> T cell help is required for the maintenance of CTL and control of viremia. Furthermore, these facts suggest the hypothesis that the immune response induced by HIV infection might be insufficient, in part due to the evolution of HIV epitopes under immune selective pressure to evade the immune response. Therefore, the virus might be controlled by a vaccine incorporating improved CD4<sup>+</sup> epitopes substituted at some amino acid positions to induce a stronger CD4<sup>+</sup> T cell response for helping HIV-specific CTL proliferation, together with similarly enhanced CTL epitopes. This approach of epitope enhancement could enable us to develop a more effective HIV vaccine (10–12). Whereas epitope enhancement has been ap-

plied to several peptides binding class I HLA molecules, there is little experience doing so for epitopes binding to class II HLA molecules for which binding motifs are less well defined.

The T1 Ag is a 16-mer peptide (KQIINMWQEVGKAMYA) CD4 epitope that was the first helper epitope discovered in the HIV envelope protein (13). Immunization with this peptide can induce an epitope-specific CD4 response in mice (restricted to H-2<sup>b</sup>, H-2<sup>d</sup>, H-2<sup>k</sup>, and H-2<sup>s</sup> (14, 15)), and the same epitope is recognized by human T cells from HIV-infected or immunized individuals (16, 17). Furthermore, a gain in potency for CD4 response is observed when 436E (glutamic acid) in the T1 epitope is replaced with A (alanine) in mice (18–20), suggesting that substitution of residues that interfere with binding might allow the design of a more potent vaccine. However, this substitution of residues enhances binding to one murine class II MHC molecule. Little is known about the HLA class II restriction of this epitope in humans. We, therefore, wanted to identify other amino acid substitutions that would improve presentation by human class II HLA molecules, to design a more effective vaccine. For this reason, we developed a T1-specific CD4<sup>+</sup> T cell line from a healthy volunteer immunized with a canarypox virus vector expressing HIV gp120 and boosted with rgp120. Using this human CD4<sup>+</sup> T cell line restricted by an HLA-DR molecule common in both the United States and Africa, we show the possibility of inducing a stronger HIV-specific CD4<sup>+</sup> T cell response by stimulation with an epitope-enhanced T1 peptide. This may be a valuable component of a second generation HIV vaccine.

## Materials and Methods

### Synthetic peptide

Peptides were prepared in an automated multiple peptide synthesizer (Symphony; Protein Technologies) using F-moc chemistry. They were purified by reverse-phase HPLC, and their sequences were confirmed, where needed, on an automated sequencer (477A; Applied Biosystems) or by amino acid analysis. Peptide purity was determined by a single peak on reverse-phase HPLC, and by amino acid analysis. Where necessary, sequencing and/or mass spectrometry were also performed.

### Immunized blood donor

The healthy HIV-negative volunteer, JO22A304X, had been immunized previously with a canarypox virus vector expressing HIV gp120 as part of

\*Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; †Immunex, Seattle, WA 98101; and ‡Johns Hopkins University Center for Immunization Research, Baltimore, MD 21205

Received for publication November 23, 2005. Accepted for publication January 6, 2006.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This work was supported by the intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.

<sup>2</sup> Current address: Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8511, Japan.

<sup>3</sup> Current address: Division of Hepatology and Gene Therapy, School of Medicine, Foundation for Applied Medical Research, University of Navarra, Irunlarrea 1, 31008 Pamplona, Spain.

<sup>4</sup> Current address: Berlex Laboratories, 1513 16th Avenue East, Seattle, WA 98112.

<sup>5</sup> Address correspondence and reprint requests to Dr. Jay A. Berzofsky, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 6B-12 (MSC 1578), National Institutes of Health, Bethesda, MD 20892-1578. E-mail address: berzofsk@helix.nih.gov

AVEG clinical protocol 022A. Human studies were approved by an appropriate institutional review board, and were conducted with the informed consent of the subject. Briefly, the blood donor was immunized with ALVAC (vCP205) at months 0 and 1 and was boosted with ALVAC and Chiron's rgp120 at months 3, 6, 9, and 12. Chiron's rgp120 has the T1 Ag of the SF2 strain of HIV-1, whose amino acid sequence is KQIINMWQEVGKAMYA,

#### Monocyte-derived dendritic cell preparation

After thawing frozen stocks of PBMCs from the donor,  $5 \times 10^6$  PBMCs were cultured with 1000 U/ml human GM-CSF and 1000 U/ml human IL-4 in a 6-well culture plate in RPMI 1640 medium containing 10% autologous plasma. Human GM-CSF and human IL-4 were added every other day to grow out dendritic cells. After pulsing with an appropriate concentration of peptide, 3  $\mu$ g/ml soluble CD40-ligand (provided by E. Thomas, Immunex, Seattle, WA) was added to the culture at day 4 to mature the dendritic cells. Maturation of dendritic cells was confirmed by up-regulation of CD83 measured by flow cytometry. The next day, after being harvested, irradiated with 10,000 rad, and washed three times, the cultured cells enriched in monocyte-derived dendritic cells were used as an APC source for T cell culture development and maintenance. However, peptide pulsing was not done in the preparation of these APCs for proliferation assays; rather, soluble peptide was titrated in the wells with the APCs and T cells in the culture.

#### Generation of peptide-specific CD4<sup>+</sup> T cell line

A total of  $5 \times 10^5$ /well freshly isolated PBMCs obtained from the healthy donor immunized with a canarypox virus vector expressing HIV gp120 and boosted with rgp120 was cultured with 3  $\mu$ M T1 peptide in 96-well U-bottom plates in R2E (RPMI 1640:Eagle-Hanks' amino acid medium = 1:1) medium containing 10% autologous plasma. On day 7,  $1 \times 10^6$  cultured cells were restimulated with  $8 \times 10^4$  irradiated monocyte-derived dendritic cells pulsed with 0.01  $\mu$ M T1 peptide in a 48-well culture plate. One day after each restimulation, T cell growth factor (CELLKINES TCGF, as a source of natural human IL-2 from human lymphocytes; Zepotomatrix) was added to a final concentration of 10%. Cell lines were maintained in R2E containing 10% autologous plasma, 1 mM sodium pyruvate, nonessential amino acids (Biofluids), 4 mM glutamine, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, and 50  $\mu$ M 2-ME. Autologous plasma was positive for anti-gp120 Abs, but such Abs generally do not affect presentation of peptide Ag bound to class II MHC molecules. After checking the Ag-specific response, the cell line (KT9) was restimulated every other week for maintenance using the same conditions as for its original establishment (with irradiated monocyte-derived dendritic cells pulsed with 0.01  $\mu$ M T1 peptide).

#### Proliferation assay

T cell proliferation was assessed by culturing  $5 \times 10^4$  KT9 cells with  $1 \times 10^4$  autologous monocyte-derived dendritic cells with or without antigenic peptide in 200  $\mu$ l of R2E medium containing 10% autologous plasma in 96-well U-bottom culture plates for 3 days. KT9 cells were used in a resting state after 2 wk of rest, just before the next restimulation. (Proliferation assays were done on the same day as, and in parallel with, restimulation of the remaining cells of the line.) Cultures were pulsed with 1  $\mu$ Ci of [<sup>3</sup>H]thymidine/well for the last 24 h. Plates were harvested and counted in a 1205 Betaplate counter (Wallac). All samples were analyzed in triplicate, and all experiments were performed at least twice with comparable results.

#### IFN- $\gamma$ assay

A total of  $4 \times 10^5$  KT9 cells and  $4 \times 10^4$  monocyte-derived dendritic cells were cultured with or without peptide at 10  $\mu$ M in 96-well U-bottom plate. Seventy-two hours later, each supernatant was collected, and IFN- $\gamma$  in the culture supernatant was determined by ELISA kit (R&D Systems) according to the manufacturer's instructions. All samples were analyzed in triplicate.

## Results

### The T1-specific CD4 T cell line is restricted to DR13

We developed a T1-specific CD4<sup>+</sup> T cell line (KT9) from a healthy volunteer immunized with a canarypox virus vector expressing HIV gp120. KT9 was determined to be CD4<sup>+</sup> and HLA-DR restricted in an inhibition assay using anti-CD4 or anti-HLA-DR, respectively (Fig. 1A). The HLA-DR haplotype of the


volunteer was DR $\beta$ 1\*01 and DR $\beta$ 1\*13. Thus, we tested the HLA-DR restriction of this helper line using dendritic cells from the PBMCs of different volunteers sharing one or the other HLA-DR type. This helper line was restricted to DR $\beta$ 1\*13, which is common in U.S. Caucasians and is also one of the major HLA-DR haplotypes in Africa (21, 22) (Fig. 1B). It should also be noted that the lack of response to T1 with DR13-negative presenting cells clearly rules out a nonspecific mitogenic effect of the T1 peptide, and the lack of response to other peptides shown below in Figs. 2 and 3B clearly shows that the KT9 line is Ag specific.

#### Recognition specificity of KT9 using single alanine-substituted analogues

In a set of experiments to define key functional residues in the T1 peptide, peptides were synthesized with single alanine substitution for each original amino acid, except using Ser in sites at which Ala was the natural residue (Table I). All peptides were tested in an epitope-specific proliferation assay (Fig. 2). Among the 14 alanine- or serine-substituted peptides, substitutions at the first five positions (peptides 28–40) did not have any effect on the T1-specific CD4 response. However, the next six substituted peptides (peptides 40–61, except 49) induced a significantly lower response. Furthermore, two alanine-substituted T1 peptides (peptides 64 and 67) showed a slightly better response than the original peptide. Based on the data of Fig. 2 and of the peptide sequence motif pattern of DR $\beta$ 1\*13-restricted peptides (22, 23), we hypothesized that the binding core motif of the T1 peptide in humans is WQEVGKAMY.

#### Recognition property of KT9 using substituted peptides in anchor positions

In general, a typical HLA class II-binding peptide has four anchor residues within a span of nine residues in positions 1, 4, 6, and 9 from the N-terminal end. In the case of the peptide sequences presented by DR $\beta$ 1\*13, hydrophobic residues are preferentially found at positions 1 and 4. A positively charged residue is frequently present at position 6. A small or hydrophobic residue is found at position 9 (22, 23). Thus, we next investigated the characteristics of the amino acid fitted to each anchor position of the postulated T1-binding core peptide using peptides substituted with amino acids having different chemical properties. First, we used peptides with a single amino acid substituted in each anchor position (Fig. 3A). In position 1 (tryptophan in the postulated T1 core peptide), alanine (small)- and isoleucine (aliphatic)-substituted T1 made the response worse. However, a phenylalanine (aromatic) substitution did not reduce the response. This result suggested that an aromatic amino acid is required in position 1. In position 4, the alanine- and phenylalanine-substituted T1 elicited a poor response from KT9. However, the isoleucine substitution induced much better helper response. This result suggested position 4 as anchor should be an aliphatic amino acid and isoleucine could enhance the Ag-specific response of the T1-specific CD4<sup>+</sup> T cell line. In contrast, in position 6, only a positively charged amino acid-substituted peptide induced a better T1-specific response. The positively charged arginine (R) at position 6 might be better binding to HLA-DR $\beta$ 1\*13 because its pK is higher (~12.5 for R vs ~10.5 for K). In position 9, all peptides substituted with small, aromatic, or aliphatic amino acids induced a better CD4 response than the original peptide. Also, in a titration assay, KT 9 stimulated with the substituted peptides that had induced the best response in each anchor position at 10  $\mu$ M showed a better response than with the original peptide (Fig. 3B). It should be noted that peptides presented by HLA class II molecules usually need to be longer than the minimal 9-mer that spans the length of the HLA groove, and



**FIGURE 1.** HLA restriction and character of T1-specific CD4 line (KT9). *A*, Inhibition assay of KT9. Proliferation of KT9 in response to T1 peptide was inhibited with anti-CD4, CD8, HLA-DR, HLA-DQ, or control IgG. The concentration of each Ab was 10  $\mu$ g/ml. *B*, Proliferation of KT9 against APCs of different HLA-DR types partially matched with the T cell donor (DR $\beta$ 1\* (01, 13)). The haplotypes of HLA-DR used in this assay were DR $\beta$ 1\* (01, 13), DR $\beta$ 1\* (01, 11), DR $\beta$ 1\* (04, 13), and DR $\beta$ 1\* (11, 13). Error bars represent SEM of triplicate wells, and the experiment was performed twice with comparable results.


we do not know the optimal length, which could affect the magnitude of the response. Moreover, we tested and compared peptide-specific IFN- $\gamma$  production of KT9 T cells between the wild-type T1 and the altered T1 peptide 53. The altered T1 peptide induced higher IFN- $\gamma$  production by KT9 than the wild-type T1 (only peptide 53 was significantly different from the no-Ag control;  $p < 0.01$ ) (Fig. 3c). This result suggested the epitope-enhanced peptide could induce not only more active proliferation of the T1-specific CD4 T cells, but also greater CD4 T cell activation in a Th1 functional response. In other words, these results mean that a CD4 epitope does not always have the most optimal amino acid in each anchor position required for both binding to the HLA class II molecule and recognition by a CD4<sup>+</sup> T cell. At the same time, it

suggests that the peptides with a combination of substitutions in anchor positions might be able to induce a much better CD4<sup>+</sup> T cell response as a vaccine construct.

*Antigenic potency of the multiply substituted T1 peptide*

Each of three separate point mutations of the T1 peptide, V to I in position 4, K to R in position 6, and Y to A in position 9, respectively, enhanced the proliferative response of KT9 (Fig. 3). Thus, we combined all three mutations in the peptide 70 (Table I) and tested antigenic potency of this multiply substituted peptide in the proliferation assay (Fig. 4). The peptide concentration in which KT9 showed the peak proliferative response was shifted to a lower peptide concentration when using this triple combinational peptide






**FIGURE 2.** Proliferation of KT9 against T1 variant peptides with alanine substitutions. The concentration of each substituted peptide was 10  $\mu$ M. Each peptide number is listed in Table I. Error bars represent SEM of triplicate wells, and the experiment was performed twice with comparable results.

than the original peptide T1, and the activity remained substantially higher than that of the wild-type peptide at a 10-fold lower concentration. Note that the high-dose inhibition of T cell proliferation also occurs at lower peptide concentration for the triple combinational peptide than for T1, again consistent with the shift in dose-response curve. These results suggested that the epitope-enhanced peptide that has the best binding capacity in each pocket in the HLA molecule could induce the best response of the wild-type specific CD4<sup>+</sup> T cell. Also, the multiple substitutions in anchor positions do not interfere with recognition by the wild-type specific human CD4<sup>+</sup> T cell line.

We attempted to assess and rank order the modified and wild-type peptides as specific stimuli of CD4 T cell proliferation in PBMCs of four HIV<sup>+</sup> long-term nonprogressing individuals who had been typed as HLA-DR13 positive (data not shown). Unfortunately, using thymidine incorporation and CFSE dye dilution detection by flow cytometry, we detected no response to any of the peptides, including the enhanced substituted peptides, nor to the full-length IIIB gp120 envelope, in any of several repeated attempts with cells from the four donors. This is consistent with the published literature describing a rapid and profound loss of CD4<sup>+</sup>



**FIGURE 3.** Proliferation and IFN- $\gamma$  production of KT9 against peptides substituted in anchor positions. *A*, The concentration of each substituted peptide was 10  $\mu$ M. Each peptide number is listed in Table I. The position of these residues in the original T1 peptide and the corresponding motif residue preferences (22, 23) are shown below. *B*, Titration of peptides 53, 59, and 67, and the original T1 peptide in a proliferation assay of KT9 T cells. Error bars represent SEM of triplicate wells, and the experiment was performed twice with comparable results. *C*, Comparison of peptide-specific IFN- $\gamma$  production between the wild-type T1 and the altered T1 peptide 53.

Table I. Peptides used in this study<sup>a</sup>

	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443
T1	K	Q	I	I	N	M	W	Q	E	V	G	K	A	M	Y	A
28	-	A	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	-	-	A	-	-	-	-	-	-	-	-	-	-	-	-	-
34	-	-	-	A	-	-	-	-	-	-	-	-	-	-	-	-
37	-	-	-	-	A	-	-	-	-	-	-	-	-	-	-	-
40	-	-	-	-	-	A	-	-	-	-	-	-	-	-	-	-
43	-	-	-	-	-	-	A	-	-	-	-	-	-	-	-	-
44	-	-	-	-	-	-	F	-	-	-	-	-	-	-	-	-
45	-	-	-	-	-	-	I	-	-	-	-	-	-	-	-	-
46	-	-	-	-	-	-	-	A	-	-	-	-	-	-	-	-
49	-	-	-	-	-	-	-	-	A	-	-	-	-	-	-	-
52	-	-	-	-	-	-	-	-	-	A	-	-	-	-	-	-
53	-	-	-	-	-	-	-	-	-	I	-	-	-	-	-	-
54	-	-	-	-	-	-	-	-	-	F	-	-	-	-	-	-
55	-	-	-	-	-	-	-	-	-	-	A	-	-	-	-	-
58	-	-	-	-	-	-	-	-	-	-	-	A	-	-	-	-
59	-	-	-	-	-	-	-	-	-	-	-	R	-	-	-	-
60	-	-	-	-	-	-	-	-	-	-	-	E	-	-	-	-
61	-	-	-	-	-	-	-	-	-	-	-	-	S	-	-	-
64	-	-	-	-	-	-	-	-	-	-	-	-	-	A	-	-
67	-	-	-	-	-	-	-	-	-	-	-	-	-	-	A	-
68	-	-	-	-	-	-	-	-	-	-	-	-	-	-	F	-
69	-	-	-	-	-	-	-	-	-	-	-	-	-	-	I	-
70	-	-	-	-	-	-	-	-	-	I	-	R	-	-	A	-

<sup>a</sup> The sequences of T1 and the various substituted analogs are given in single letter amino acid code. Numbers at the top of each column refer to positions in the HIV-1 IIIB gp160 protein. Dashes in each row indicate that the residue at that position in that peptide is the same as T1.


proliferative response to HIV envelope even among long-term nonprogressors (24–29).

## Discussion

The T1 Ag was the first CD4 helper epitope discovered in the HIV envelope protein (13, 16, 17). A CD4 response specific for this epitope could be observed in some HIV-seropositive individuals in the United States and healthy volunteers vaccinated with gp160 in Zaire, Africa (16, 17). These facts indicated that the T1 epitope is obviously presented by some relatively prevalent human HLA class II molecules. However, the actual class II restriction of T1-specific CD4<sup>+</sup> T cells remained yet to be clarified. In this study, we developed a T1-specific human CD4<sup>+</sup> T cell line (KT9) from a healthy Caucasian American volunteer immunized with a canarypox virus vector expressing gp120 and found that this CD4 helper line is restricted to DRβ1\*13 (Fig. 1*b*). DR13 is one of the major haplotypes in Africa, where there are >25 million HIV-infected patients (30), and is also common in U.S. Caucasians as well as African-Americans (22). Thus, the T1 Ag could be a very

useful CD4 epitope as an HIV vaccine component in North America and Africa. Because HIV epitopes may have evolved to evade the immune system, we applied epitope enhancement by sequence modification to increase the potency of this epitope.

To achieve a stronger CD4<sup>+</sup> T cell response against this T1 epitope, we tested the proliferative response of KT9 against some amino acid-substituted variants of T1 peptide. Except for two cases, T1 peptides with alanine substituted in each position could not induce a stronger proliferative response from KT9 than the original T1 (Fig. 2). However, we could identify the likely binding core as WQEVGKAMY based on the alanine substitutions that diminished recognition, together with proliferation assay data using truncated peptides of T1 (data not shown). Most HLA-DR-binding core sequence motifs typically have four anchor residues. An aromatic amino acid and an aliphatic amino acid are preferentially found in positions 1 and 4, respectively (Fig. 3). Although the substitution of phenylalanine for tryptophan in position 1 did not produce a better CD4 response, the substitution of isoleucine for valine in the T1 peptide increased proliferation of KT9 up to 2-fold over the original T1-stimulated response. Both valine and isoleucine belong to the same aliphatic branched chain amino acid group. This suggests that there might be a hierarchy for binding to pockets of HLA-DR molecules among amino acids in a same group. Position 6 is thought to be an allele-specific anchor (31). In the case of DR13, a positively charged amino acid is preferable. Also from our data (Fig. 3), a replacement of lysine by the positively charged amino acid with a higher pK, arginine, in position 6 enhanced the CD4 response. The replacement by this positively charged amino acid with a higher pK (12.5 vs 10.5 for lysine) in this allele-specific anchor position might be a broadly applicable method for epitope enhancement of CD4 epitopes presented by DR13. However, more confirmation using many different DR13-binding peptides would be required to confirm the generality of this approach. It is of interest that although the T1 sequence is relatively conserved, being in the CD4 binding site, the position 6 residue is essentially always K in clade B viruses, mostly R in



**FIGURE 4.** Proliferation of KT9 with multiply substituted peptide (70) and the original T1 peptide. Data represent means of triplicate wells, and the experiment was performed twice with comparable results.

clade C viruses, and either K, R, or Q in clade A viruses. All three of these alternatives can be accommodated in the DR13-binding motif.

In our previous paper, we showed that an epitope-enhanced HIV CTL epitope substituted with the appropriate amino acids in all class I MHC anchor positions can induce a better CTL response *in vitro* and *in vivo*, and further that the anchor-enhanced epitope-specific CTL can recognize the wild-type epitope with complete cross-reactivity (32). Other enhanced CTL epitopes from HIV-1 reverse-transcriptase binding better to a class I molecule have been described (33). However, it is equally important to determine whether the epitope-enhancement strategy could magnify the activation of human HIV-specific CD4<sup>+</sup> T cells recognizing a peptide binding to a human class II HLA molecule to help the expansion and maintenance for HIV-specific CTLs. Yet, there is little experience with epitope enhancement for peptides binding human class II HLA molecules.

The importance of improving the CD4<sup>+</sup> T cell response as well as the CD8<sup>+</sup> T cell response is becoming more apparent as more is known about the importance of CD4<sup>+</sup> T cell help in inducing a long-lived memory CD8<sup>+</sup> T cell response (5, 7–9, 34). In a mouse model using a T1 variant with higher affinity for a mouse class II MHC molecule, we found that this enhanced peptide induced not only a stronger CD4<sup>+</sup> T cell response, but shifted the quality of the response toward Th1 by up-regulating CD40 ligand on the helper cells and polarizing dendritic cells to make IL-12, and thus shifting the cytokine profile of the helper cells and inducing a stronger CTL response to an attached CTL epitope (19, 20). The result was better protection against viral challenge in the mouse model. Thus, we tested whether this principle could be true for the epitope enhancement of this human HIV CD4 epitope using KT9.

The multiply substituted peptide 70 shifted the peak proliferative response of KT9 to lower concentrations (Fig. 4). An epitope-enhanced peptide also showed a stronger IFN- $\gamma$  response (Fig. 3c). The result suggested that the epitope-enhanced HIV CD4 epitope substituted with appropriate combinations of anchor residues could also induce a stronger wild-type specific CD4<sup>+</sup> T cell response. However, it will also be important to determine the portion of the CD4 T cell repertoire specific for the enhanced peptide that cross-reacts with the wild-type epitope, for example, immunizing humans with the enhanced peptide, or using HLA-DR13 transgenic mice, as described in our previous paper on enhancing an HLA class I-restricted epitope (26). Such an epitope-enhancement strategy could induce stronger CD4 responses in humans that might provide more effective CD4<sup>+</sup> T cell-mediated help for CTL maintenance against HIV. A similar strategy could be applicable to any Ag for which an optimal CD4<sup>+</sup> and CD8<sup>+</sup> T cell response is desirable.

Our findings show that modifying this HIV CD4 epitope with some amino acid substitutions in anchor regions for epitope enhancement could magnify the T1-specific CD4 helper response compared with the original T1 peptide. Of course, enhanced antigenicity *in vivo* may not necessarily translate into enhanced immunogenicity *in vivo*, although it often does. This cannot be determined without a clinical trial, for which this study provides the preclinical data and motivation. Furthermore, the T1 peptide is just one of a number of HIV CD4 epitopes. This strategy would be more effective when applied to multiple conserved CD4 epitopes in HIV, as well as to HIV CTL epitopes, as we recently described (32). Also, these studies provide a rational strategy for the construction of enhanced epitopes that can be applied to build the next generation vaccines, applicable to all forms of vaccine, peptide, DNA, recombinant viral or bacterial vector, or live attenuated virus.

## Acknowledgments

We thank Drs. Roland Martin and Barbara Rehermann for critical reading of the manuscript and helpful suggestions. We thank Drs. Jeffrey D. Ahlers, Igor Belyakov, Amiran Dzutsev, SangKon Oh, Jong Myun Park, James T. Snyder, Masaki Terabe, and Leon van den Broeke for helpful discussion, and Lisa Smith for secretarial assistance. We are also grateful for the generosity of the blood donor JO22A304X in repeatedly donating his blood, and to Eric Zimmerman, Cass Jones, Karen Madaras, and Kimberly Camp for generous help in the blood collection. We thank Dr. Mark Connors and Dr. Stephen A. Migueles for a kind gift of several aliquots of PBMCs from each of four long-term nonprogressor HIV-infected blood donors.

## Disclosures

The authors have no financial conflict of interest.

## References

- Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. D. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. *J. Exp. Med.* 188: 2205–2213.
- Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. *N. Engl. J. Med.* 333: 1038–1044.
- Cardin, R. D., J. W. Brooks, S. R. Sarawar, and P. C. Doherty. 1996. Progressive loss of CD8<sup>+</sup> T cell-mediated control of a  $\gamma$ -herpesvirus in the absence of CD4<sup>+</sup> T cells. *J. Exp. Med.* 184: 863–871.
- Hasenkrug, K. J., D. M. Brooks, and U. Dittmer. 1998. Critical role for CD4<sup>+</sup> T cells in controlling retrovirus replication and spread in persistently infected mice. *J. Virol.* 72: 6559–6564.
- Rosenberg, E. S., J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker. 1997. Vigorous HIV-1-specific CD4<sup>+</sup> T cell responses associated with control of viremia. *Science* 278: 1447–1450.
- Rosenberg, E. S., M. Altfeld, S. H. Poon, M. N. Phillips, B. M. Wilkes, R. L. Eldridge, G. K. Robbins, R. T. D'Aquila, P. J. Goulder, and B. D. Walker. 2000. Immune control of HIV-1 after early treatment of acute infection. *Nature* 407: 523–526.
- Janssen, E. M., E. E. Lemmens, T. Wolfe, U. Christen, M. G. von Herrath, and S. P. Schoenberg. 2003. CD4<sup>+</sup> T cells are required for secondary expansion and memory in CD8<sup>+</sup> T lymphocytes. *Nature* 421: 852–856.
- Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. *Science* 300: 337–339.
- Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. *Science* 300: 339–342.
- Berzofsky, J. A. 1993. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines. *Ann. NY Acad. Sci.* 690: 256–264.
- Berzofsky, J. A., J. D. Ahlers, M. A. Derby, C. D. Pendleton, T. Arichi, and I. M. Belyakov. 1999. Approaches to improve engineered vaccines for human immunodeficiency virus (HIV) and other viruses that cause chronic infections. *Immunol. Rev.* 170: 151–172.
- Berzofsky, J. A., J. D. Ahlers, and I. M. Belyakov. 2001. Strategies for designing and optimizing new generation vaccines. *Nat. Rev. Immunol.* 1: 209–219.
- Cease, K. B., H. Margalit, J. L. Cornette, S. D. Putney, W. G. Robey, C. Ouyang, H. Z. Streicher, P. J. Fischinger, R. C. Gallo, G. M. DeLisi, and J. A. Berzofsky. 1987. Helper T cell antigenic site identification in the AIDS virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. *Proc. Natl. Acad. Sci. USA* 84: 4249–4253.
- Hale, P. M., K. B. Cease, R. A. Houghten, C. Ouyang, S. Putney, K. Javaherian, H. Margalit, J. L. Cornette, J. L. Spouge, C. DeLisi, and J. A. Berzofsky. 1989. T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction. *Int. Immunol.* 1: 409–415.
- Berzofsky, J. A., C. D. Pendleton, M. Clerici, J. Ahlers, D. R. Lucey, S. D. Putney, and G. M. Shearer. 1991. Construction of peptides encompassing multideterminant clusters of HIV envelope to induce *in vitro* T-cell responses in mice and humans of multiple MHC types. *J. Clin. Invest.* 88: 876–884.
- Clerici, M., N. I. Stocks, R. A. Zajac, R. N. Boswell, D. C. Bernstein, D. L. Mann, G. M. Shearer, and J. A. Berzofsky. 1989. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV seropositive individuals. *Nature* 339: 383–385.
- Berzofsky, J. A., A. Bensussan, K. B. Cease, J. F. Bourge, R. Cheynier, Z. Lurhuma, J.-J. Salatin, R. C. Gallo, G. M. Shearer, and D. Zagury. 1988. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. *Nature* 334: 706–708.
- Boehnecke, W.-H., T. Takeshita, C. D. Pendleton, S. Sadegh-Nasserli, L. Racioppi, R. A. Houghten, J. A. Berzofsky, and R. N. Germain. 1993. The importance of dominant negative effects of amino acids side chain substitution in peptide-MHC molecule interactions and T cell recognition. *J. Immunol.* 150: 331–341.
- Ahlers, J. D., T. Takeshita, C. D. Pendleton, and J. A. Berzofsky. 1997. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. *Proc. Natl. Acad. Sci. USA* 94: 10856–10861.

20. Ahlers, J. D., I. M. Belyakov, E. K. Thomas, and J. A. Berzofsky. 2001. High affinity T-helper epitope induces complementary helper and APC polarization, increased CTL and protection against viral infection. *J. Clin. Invest.* 108: 1677–1685.
21. Sintasath, D. M., T. Tang, R. Slack, E. E. Tilley, J. Ng, R. J. Hartzman, and C. K. Hurley. 1999. Relative HLA-DRB1\*13 allele frequencies and DRB3 associations of unrelated individuals from five U.S. populations. *Hum. Immunol.* 60: 1001–1010.
22. Verreck, F. A., A. van de Poel, J. W. Drijfhout, R. Amons, J. E. Coligan, and F. Konig. 1996. Natural peptides isolated from Gly86/Val86-containing variants of HLA-DR1, -DR11, -DR13, and -DR52. *Immunogenetics* 43: 392–397.
23. Davenport, M. P., C. L. Quinn, R. M. Chicz, B. N. Green, A. C. Willis, W. S. Lane, J. I. Bell, and A. V. Hill. 1995. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR  $\beta$  chain. *Proc. Natl. Acad. Sci. USA* 92: 6567–6571.
24. Shearer, G. M., S. M. Payne, L. J. Joseph, and W. E. Biddison. 1984. Functional T lymphocyte immune deficiency in a population of homosexual men who do not exhibit symptoms of acquired immune deficiency syndrome. *J. Clin. Invest.* 74: 496–506.
25. Wahren, B., L. Morfeldt-Månsson, G. Biberfeld, L. Moberg, A. Sönnernborg, P. Ljungman, A. Werner, R. Kurth, R. Gallo, and D. Bolognesi. 1987. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. *J. Virol.* 61: 2017–2023.
26. Pontesilli, O., M. Carlesimo, A. R. Varani, R. Ferrara, E. C. Guerra, M. L. Bernardi, G. Ricci, A. M. Mazzone, G. D'Offizi, and F. Aiuti. 1995. HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. *Clin. Exp. Immunol.* 100: 419–424.
27. McNeil, A. C., W. L. Shupert, C. A. Iyasere, C. W. Hallahan, J. A. Mican, R. T. Davey, Jr., and M. Connors. 2001. High-level HIV-1 viremia suppresses viral antigen-specific CD4<sup>+</sup> T cell proliferation. *Proc. Natl. Acad. Sci. USA* 98: 13878–13883.
28. Hioe, C. E., M. Tuen, P. C. Chien, Jr., G. Jones, S. Ratto-Kim, P. J. Norris, W. J. Moretto, D. F. Nixon, M. K. Gorny, and S. Zolla-Pazner. 2001. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. *J. Virol.* 75: 10950–10957.
29. Douek, D. C., L. J. Picker, and R. A. Koup. 2003. T cell dynamics in HIV-1 infection. *Annu. Rev. Immunol.* 21: 265–304.
30. Mwau, M., and A. J. McMichael. 2003. A review of vaccines for HIV prevention. *J. Gene Med.* 5: 3–10.
31. Hammer, J., P. Valsasnini, K. Tolba, D. Bolin, J. Higelin, B. Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. *Cell* 74: 197–203.
32. Okazaki, T., D. C. Pendleton, F. Lemonnier, and J. A. Berzofsky. 2003. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. *J. Immunol.* 171: 2548–2555.
33. Pogue, R. R., J. Eron, J. A. Frelinger, and M. Matsui. 1995. Amino-terminal alteration of the HLA-A\*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. *Proc. Natl. Acad. Sci. USA* 92: 8166–8170.
34. Kaech, S. M., and R. Ahmed. 2003. Immunology: CD8 T cells remember with a little help. *Science* 300: 263–265.